Last reviewed · How we verify

NCT05870605

Drug Use Study With Intuniv® in European Countries

Completed Last updated 22 August 2023
What this trial tests

trial testing No Intervention in Attention Deficit Hyperactivity Disorder (ADHD) in 5,000 participants. Completed in 30 April 2022.

Timeline
15 November 2018
Primary endpoint
30 April 2022
30 April 2022

Quick facts

Lead sponsorShire
StatusCompleted
Study typeOBSERVATIONAL
Enrollment5,000
Start date15 November 2018
Primary completion30 April 2022
Estimated completion30 April 2022
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Shire — full company profile →

Who can join

6 and older, any sex, with Attention Deficit Hyperactivity Disorder (ADHD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate and characterize people who are taking Intuniv, analyze prescribing behaviors of physicians, and determine whether Intuniv was correctly prescribed in Belgium, Denmark, Finland, Germany, Ireland, Netherlands, Norway, Spain, Sweden, and the United Kingdom.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

Other recruiting trials for Attention Deficit Hyperactivity Disorder (ADHD)

Currently open trials in the same condition.

Other Shire trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing